Business Wire

Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced plans to initiate a Phase 3 cardiovascular outcomes trial (CVOT) ...
Seeking Alpha

Immuneering: Clinical Catalyst In January, Cash Raised For Phase 3

Immuneering is developing atebimetinib, a novel MEK inhibitor, in multiple solid tumors, having already produced impressive phase 2a data in pancreatic cancer. IMRX's near-term catalyst is the January ...
Business Wire

Vertex to Present Phase 3 Data Highlighting Suzetrigine’s Potential as a First-in-Class, Highly Selective Pain Signal Inhibitor at the American Society of Anesthesiologists ...

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the company will present its pivotal Phase 3 data on suzetrigine, an investigational, oral, highly ...
Seeking Alpha

89bio: Promising As Pegozafermin Nears Phase 3 Readout

Pegozafermin is ETNB’s long-acting FGF21 analog. It’s undergoing three Phase 3 trials. Two of those late-stage trials are for MASH (F2-F4), and the third is for severe hypertriglyceridemia. Also, ETNB ...
Nasdaq

Reviva Pharmaceuticals Reports Completion of Brilaroxazine Long-Term OLE Trial and Upcoming Phase 3 RECOVER-2 Trial Initiation

Reviva Pharmaceuticals Holdings, Inc. announced that 446 participants have completed their long-term open-label extension (OLE) trial for brilaroxazine, with 156 participants receiving one year of ...